Phase 1b Study of Eganelisib Alone and with Cytarabine in Relapsed/Refractory AML or Higher-Risk MDS

Phase 2, open-label trial of eganelisib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Stelexis Therapeutics. Primary endpoints: Incidence and severity of adverse events in Part 1 (monotherapy and combination dose escalation), Incidence and severity of dose-limiting toxicities in Part 1 (monotherapy and combination dose escalation) and 2 more. Planned start Apr 2025; status: authorised.